Computational prediction of formulation strategies for beyond-rule-of-5 compounds

Advanced Drug Delivery Reviews

Volumn 101, Issue , 2016, Pages 6-21

  Bergström, Christel A S ^a,b   Charman, William N ^a   Porter, Christopher J H ^a  

^a MONASH UNIVERSITY   (Australia)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

ADMET; Beyond rule of five; Biopharmaceutical performance; Computational prediction; Enabling formulations; Lipophilic targets; Permeability; Solubility

Indexed keywords

CHEMICAL COMPOUNDS; COMPUTATION THEORY; COMPUTATIONAL METHODS; FORECASTING; MECHANICAL PERMEABILITY; MOLECULAR DYNAMICS; PHYSIOLOGY; SOLUBILITY;

ADMET; BEYOND RULE-OF-FIVE; BIOPHARMACEUTICAL PERFORMANCE; COMPUTATIONAL PREDICTIONS; ENABLING FORMULATIONS;

PHYSIOLOGICAL MODELS;

ARIPIPRAZOLE; CANNABINOID RECEPTOR; CHOLESTEROL ESTER TRANSFER PROTEIN; CIPROFLOXACIN; EXCIPIENT; FARNESOID X RECEPTOR; GAMMA SECRETASE INHIBITOR; GLYCOPROTEIN GP 120; LEVOFLOXACIN; MACROLIDE; MELATONIN RECEPTOR; PHOSPHOLIPID; QUINOLONE; RETINOIC ACID RECEPTOR; TRAMADOL; DRUG;

BIOEQUIVALENCE; CELL TRANSPORT; CONFORMATIONAL TRANSITION; DEVELOPMENTAL STAGE; DISPERSION; DRUG ABSORPTION; DRUG CAPSULE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG INDUSTRY; DRUG METABOLISM; DRUG SOLUBILITY; HYDROGEN BOND; HYDROPHILICITY; INTESTINE FLUID; LIPOPHILICITY; MEMBRANE PERMEABILITY; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOLECULAR WEIGHT; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE PROPERTY RELATION; REVIEW; SOLVATION; STOMACH JUICE; TABLET FORMULATION; THERMODYNAMICS; BODY FLUID; CHEMISTRY; INTESTINE; INTESTINE ABSORPTION; METABOLISM; SOLUBILITY;

BODY FLUIDS; DRUG COMPOUNDING; INTESTINAL ABSORPTION; INTESTINES; MOLECULAR DYNAMICS SIMULATION; PHARMACEUTICAL PREPARATIONS; SOLUBILITY;

EID: 84961123582     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2016.02.005     Document Type: Review

References (165)

1. [1] Wang, H., Chen, J., Hollister, K., Sowers, L.C., Forman, B.M., Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell 3 (1999), 543–553.
2. [2] Fu, X., Menke, J.G., Chen, Y., Zhou, G., MacNaul, K.L., Wright, S.D., Sparrow, C.P., Lund, E.G., 27-Hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J. Biol. Chem. 276 (2001), 38378–38387.
3. [3] Padgett, L.W., Recent developments in cannabinoid ligands. Life Sci. 77 (2005), 1767–1798.
4. [4] Hurst, D.P., Grossfield, A., Lynch, D.L., Feller, S., Romo, T.D., Gawrisch, K., Pitman, M.C., Reggio, P.H., A lipid pathway for ligand binding is necessary for a cannabinoid G protein-coupled receptor. J. Biol. Chem. 285 (2010), 17954–17964.
5. [5] Morphy, R., The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds. J. Med. Chem. 49 (2006), 2969–2978.
6. [6] Benet, L.Z., Wu, C.-Y., Custodio, J.M., Predicting drug absorption and the effects of food on oral bioavailability. Bull. Tech. Gattefossé, 2006, 9–16.
7. [7] Rane, S.S., Anderson, B.D., What determines drug solubility in lipid vehicles: is it predictable?. Adv. Drug Deliv. Rev. 60 (2008), 638–656.
8. [8] Congreve, M., Carr, R., Murray, C., Jhoti, H., A ‘rule of three’ for fragment-based lead discovery?. Drug Discov. Today 8 (2003), 876–877.
9. [9] Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeny, P.J., Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23 (1997), 3–25.
10. [10] Ritchie, T.J., Macdonald, S.J., The impact of aromatic ring count on compound developability—are too many aromatic rings a liability in drug design?. Drug Discov. Today 14 (2009), 1011–1020.
11. [11] Veber, D.F., Johnson, S.R., Cheng, H.Y., Smith, B.R., Ward, K.W., Kopple, K.D., Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 45 (2002), 2615–2623.
12. [12] Hann, M.M., Keseru, G.M., Finding the sweet spot: the role of nature and nurture in medicinal chemistry. Nat. Rev. Drug Discov. 11 (2012), 355–365.
13. [13] Waring, M.J., Arrowsmith, J., Leach, A.R., Leeson, P.D., Mandrell, S., Owen, R.M., Pairaudeau, G., Pennie, W.D., Pickett, S.D., Wang, J., Wallace, O., Weir, A., An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat. Rev. Drug Discov. 14 (2015), 475–486.
14. [14] Vieth, M., Sutherland, J.J., Dependence of molecular properties on proteomic family for marketed oral drugs. J. Med. Chem. 49 (2006), 3451–3453.
15. [15] Keseru, G.M., Makara, G.M., The influence of lead discovery strategies on the properties of drug candidates. Nat. Rev. Drug Discov. 8 (2009), 203–212.
16. [16] Leeson, P.D., Springthorpe, B., The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Discov. 6 (2007), 881–890.
17. [17] Leeson, P.D., St-Gallay, S.A., The influence of the ‘organizational factor’ on compound quality in drug discovery. Nat. Rev. Drug Discov. 10 (2011), 749–765.
18. [18] Campbell, S.J., Gaulton, A., Marshall, J., Bichko, D., Martin, S., Brouwer, C., Harland, L., Visualizing the drug target landscape. Drug Discov. Today 15 (2010), 3–15.
19. [19] Hajduk, P.J., Huth, J.R., Fesik, S.W., Druggability indices for protein targets derived from NMR-based screening data. J. Med. Chem. 48 (2005), 2518–2525.
20. [20] Schmidtke, P., Barril, X., Understanding and predicting druggability. A high-throughput method for detection of drug binding sites. J. Med. Chem. 53 (2010), 5858–5867.
21. [21] Lipinski, C., Hopkins, A., Navigating chemical space for biology and medicine. Nature 432 (2004), 855–861.
22. [22] Fauman, E.B., Rai, B.K., Huang, E.S., Structure-based druggability assessment—identifying suitable targets for small molecule therapeutics. Curr. Opin. Chem. Biol. 15 (2011), 463–468.
23. [23] Matsson, P., Doak, B.C., Over, B., Kihlberg, J., Cell permeability beyond the rule of 5. Adv. Drug Deliv. Rev. 101 (2016), 42–61.
24. [24] Kozakov, D., Hall, D.R., Napoleon, R.L., Yueh, C., Whitty, A., Vajda, S., New frontiers in druggability. J. Med. Chem., 2015.
25. [25] Krämer, S.D., Aschmann, H., Hatibovic, M., Hermann, K.F., Neuhaus, C.S., Brunner, C., Belli, S., When barriers ignore the “rule-of-five”. Adv. Drug Deliv. Rev., 2016.
26. [26] Mayer, J.M., van de Waterbeemd, H., Development of quantitative structure–pharmacokinetic relationships. Environ. Health Perspect. 61 (1985), 295–306.
27. [27] Bergstrom, C.A., Wassvik, C.M., Norinder, U., Luthman, K., Artursson, P., Global and local computational models for aqueous solubility prediction of drug-like molecules. J. Chem. Inf. Comput. Sci. 44 (2004), 1477–1488.
28. [28] Palmer, D.S., Mitchell, J.B., Is experimental data quality the limiting factor in predicting the aqueous solubility of druglike molecules?. Mol. Pharm. 11 (2014), 2962–2972.
29. [29] Palm, K., Luthman, K., Ungell, A.L., Strandlund, G., Beigi, F., Lundahl, P., Artursson, P., Evaluation of dynamic polar molecular surface area as predictor of drug absorption: comparison with other computational and experimental predictors. J. Med. Chem. 41 (1998), 5382–5392.
30. [30] Palm, K., Stenberg, P., Luthman, K., Artursson, P., Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm. Res. 14 (1997), 568–571.
31. [31] Stenberg, P., Luthman, K., Artursson, P., Prediction of membrane permeability to peptides from calculated dynamic molecular surface properties. Pharm. Res. 16 (1999), 205–212.
32. [32] Ertl, P., Rohde, B., Selzer, P., Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J. Med. Chem. 43 (2000), 3714–3717.
33. [33] Stenberg, P., Norinder, U., Luthman, K., Artursson, P., Experimental and computational screening models for the prediction of intestinal drug absorption. J. Med. Chem. 44 (2001), 1927–1937.
34. [34] Norinder, U., Bergstrom, C.A., Prediction of ADMET properties. ChemMedChem 1 (2006), 920–937.
35. [35] Glassey, J., Multivariate data analysis for advancing the interpretation of bioprocess measurement and monitoring data. Advances in Biochemical Engineering Biotechnology, 2013, Springer-Verlag, Berlin Heidelberg, 167–191.
36. [36] Bergstrom, C.A., Wassvik, C.M., Johansson, K., Hubatsch, I., Poorly soluble marketed drugs display solvation limited solubility. J. Med. Chem. 50 (2007), 5858–5862.
37. [37] Wassvik, C.M., Holmen, A.G., Draheim, R., Artursson, P., Bergstrom, C.A., Molecular characteristics for solid-state limited solubility. J. Med. Chem. 51 (2008), 3035–3039.
38. [38] Jain, N., Yalkowsky, S.H., Estimation of the aqueous solubility I: application to organic nonelectrolytes. J. Pharm. Sci. 90 (2001), 234–252.
39. [39] Briggner, L.E., Kloo, L., Rosdahl, J., Svensson, P.H., In silico solid state perturbation for solubility improvement. ChemMedChem 9 (2014), 724–726.
40. [40] Fagerberg, J.H., Tsinman, O., Sun, N., Tsinman, K., Avdeef, A., Bergstrom, C.A., Dissolution rate and apparent solubility of poorly soluble drugs in biorelevant dissolution media. Mol. Pharm., 2010.
41. [41] Schnieders, M.J., Baltrusaitis, J., Shi, Y., Chattree, G., Zheng, L., Yang, W., Ren, P., The structure, thermodynamics and solubility of organic crystals from simulation with a polarizable force field. J. Chem. Theory Comput. 8 (2012), 1721–1736.
42. [42] Bardwell, D.A., Adjiman, C.S., Arnautova, Y.A., Bartashevich, E., Boerrigter, S.X., Braun, D.E., Cruz-Cabeza, A.J., Day, G.M., Valle, R.G. Della, Desiraju, G.R., van Eijck, B.P., Facelli, J.C., Ferraro, M.B., Grillo, D., Habgood, M., Hofmann, D.W., Hofmann, F., Jose, K.V., Karamertzanis, P.G., Kazantsev, A.V., Kendrick, J., Kuleshova, L.N., Leusen, F.J., Maleev, A.V., Misquitta, A.J., Mohamed, S., Needs, R.J., Neumann, M.A., Nikylov, D., Orendt, A.M., Pal, R., Pantelides, C.C., Pickard, C.J., Price, L.S., Price, S.L., Scheraga, H.A., van de Streek, J., Thakur, T.S., Tiwari, S., Venuti, E., Zhitkov, I.K., Towards crystal structure prediction of complex organic compounds—a report on the fifth blind test. Acta Crystallogr. Sect. B: Struct. Sci. 67 (2011), 535–551.
43. [43] Bergstrom, C.A., Norinder, U., Luthman, K., Artursson, P., Molecular descriptors influencing melting point and their role in classification of solid drugs. J. Chem. Inf. Comput. Sci. 43 (2003), 1177–1185.
44. [44] Dearden, J.C., Rotureau, P., Fayet, G., QSPR prediction of physico-chemical properties for REACH. SAR QSAR Environ. Res. 24 (2013), 279–318.
45. [45] Bergstrom, C.A., Holm, R., Jorgensen, S.A., Andersson, S.B., Artursson, P., Beato, S., Borde, A., Box, K., Brewster, M., Dressman, J., Feng, K.I., Halbert, G., Kostewicz, E., McAllister, M., Muenster, U., Thinnes, J., Taylor, R., Mullertz, A., Early pharmaceutical profiling to predict oral drug absorption: current status and unmet needs. Eur. J. Pharm. Sci. 57 (2014), 173–199.
46. [46] Diakidou, A., Vertzoni, M., Goumas, K., Soderlind, E., Abrahamsson, B., Dressman, J., Reppas, C., Characterization of the contents of ascending colon to which drugs are exposed after oral administration to healthy adults. Pharm. Res. 26 (2009), 2141–2151.
47. [47] Reppas, C., Karatza, E., Goumas, C., Markopoulos, C., Vertzoni, M., Characterization of contents of distal ileum and cecum to which drugs/drug products are exposed during bioavailability/bioequivalence studies in healthy adults. Pharm. Res. 32 (2015), 3338–3349.
48. [48] Kossena, G.A., Charman, W.N., Wilson, C.G., O'Mahony, B., Lindsay, B., Hempenstall, J.M., Davison, C.L., Crowley, P.J., Porter, C.J., Low dose lipid formulations: effects on gastric emptying and biliary secretion. Pharm. Res. 24 (2007), 2084–2096.
49. [49] Fagerberg, J.H., Karlsson, E., Ulander, J., Hanisch, G., Bergstrom, C.A., Computational prediction of drug solubility in fasted simulated and aspirated human intestinal fluid. Pharm. Res. 32 (2015), 578–589.
50. [50] ADMET Predictor. See www.simulations-plus.com.
51. [51] Bergstrom, C.A., Strafford, M., Lazorova, L., Avdeef, A., Luthman, K., Artursson, P., Absorption classification of oral drugs based on molecular surface properties. J. Med. Chem. 46 (2003), 558–570.
52. [52] Mahlin, D., Ponnambalam, S., Hockerfelt, M.H., Bergstrom, C.A., Toward in silico prediction of glass-forming ability from molecular structure alone: a screening tool in early drug development. Mol. Pharm. 8 (2011), 498–506.
53. [53] Fagerberg, J.H., Bergstrom, C.A., Intestinal solubility and absorption of poorly water soluble compounds: predictions, challenges and solutions. Ther. Deliv. 6 (2015), 935–959.
54. [54] Zaki, N.M., Artursson, P., Bergstrom, C.A., A modified physiological BCS for prediction of intestinal absorption in drug discovery. Mol. Pharm. 7 (2010), 1478–1487.
55. [55] Wassvik, C.M., Holmen, A.G., Bergstrom, C.A., Zamora, I., Artursson, P., Contribution of solid-state properties to the aqueous solubility of drugs. Eur. J. Pharm. Sci. 29 (2006), 294–305.
56. [56] Persson, L.C., Porter, C.J., Charman, W.N., Bergstrom, C.A., Computational prediction of drug solubility in lipid based formulation excipients. Pharm. Res. 30 (2013), 3225–3237.
57. [57] Ritchie, T.J., Macdonald, S.J., Young, R.J., Pickett, S.D., The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types. Drug Discov. Today 16 (2011), 164–171.
58. [58] Lovering, F., Bikker, J., Humblet, C., Escape from flatland: increasing saturation as an approach to improving clinical success. J. Med. Chem. 52 (2009), 6752–6756.
59. [59] Young, R.J., Green, D.V., Luscombe, C.N., Hill, A.P., Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity. Drug Discov. Today 16 (2011), 822–830.
60. [60] Salentinig, S., Phan, S., Hawley, A., Boyd, B.J., Self-assembly structure formation during the digestion of human breast milk. Angew. Chem. 54 (2015), 1600–1603.
61. [61] www.fass.se accessed November 25, 2015.
62. [62] Camenisch, G., Alsenz, J., van de Waterbeemd, H., Folkers, G., Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight. Eur. J. Pharm. Sci. 6 (1998), 317–324.
63. [63] Matsson, P., Pedersen, J.M., Norinder, U., Bergstrom, C.A., Artursson, P., Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm. Res. 26 (2009), 1816–1831.
64. [64] Mateus, A., Matsson, P., Artursson, P., Rapid measurement of intracellular unbound drug concentrations. Mol. Pharm. 10 (2013), 2467–2478.
65. [65] Yabe, Y., Galetin, A., Houston, J.B., Kinetic characterization of rat hepatic uptake of 16 actively transported drugs. Drug Metab. Dispos. 39 (2011), 1808–1814.
66. [66] Matsson, P., Bergstrom, C.A., Nagahara, N., Tavelin, S., Norinder, U., Artursson, P., Exploring the role of different drug transport routes in permeability screening. J. Med. Chem. 48 (2005), 604–613.
67. [67] Matsson, P., Bergstrom, C.A., Computational modeling to predict the functions and impact of drug transporters. In Silico Pharmacology 3 (2015), 1–8.
68. [68] Lennernäs, H., Palm, K., Fagerholm, U., Artursson, P., Comparison between active and passive drug transport in human intestinal epithelial (Caco-2) cells in vitro and human jejunum in vivo. Int. J. Pharm. 127 (1996), 103–107.
69. [69] Tavelin, S., Milovic, V., Ocklind, G., Olsson, S., Artursson, P., A conditionally immortalized epithelial cell line for studies of intestinal drug transport. J. Pharmacol. Exp. Ther. 290 (1999), 1212–1221.
70. [70] Dahlgren, D., Roos, C., Sjogren, E., Lennernas, H., Direct in vivo human intestinal permeability (Peff) determined with different clinical perfusion and intubation methods. J. Pharm. Sci. 104 (2015), 2702–2726.
71. [71] Palmer, D.S., Misin, M., Fedorov, M.V., Llinas, A., Fast and general method to predict the physicochemical properties of druglike molecules using the integral equation theory of molecular liquids. Mol. Pharm. 12 (2015), 3420–3432.
72. [72] Sun, L., Liu, X., Xiang, R., Wu, C., Wang, Y., Sun, Y., Sun, J., He, Z., Structure-based prediction of human intestinal membrane permeability for rapid in silico BCS classification. Biopharm. Drug Dispos. 34 (2013), 321–335.
73. [73] Shinkai, H., Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents. Expert Opin. Ther. Pat. 19 (2009), 1229–1237.
74. [74] Leeson, P.D., Molecular inflation, attrition and the rule of five. Adv. Drug Deliv. Rev., 2016.
75. [75] Trieselmann, T., Wagner, H., Fuchs, K., Hamprecht, D., Berta, D., Cremonesi, P., Streicher, R., Luippold, G., Volz, A., Markert, M., Nar, H., Potent cholesteryl ester transfer protein inhibitors of reduced lipophilicity: 1,1′-spiro-substituted hexahydrofuroquinoline derivatives. J. Med. Chem. 57 (2014), 8766–8776.
76. [76] Amidon, G.L., Lennernas, H., Shah, V.P., Crison, J.R., A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12 (1995), 413–420.
77. [77] Wu, C.Y., Benet, L.Z., Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 22 (2005), 11–23.
78. [78] Doss, G.A., Baillie, T.A., Addressing metabolic activation as an integral component of drug design. Drug Metab. Rev. 38 (2006), 641–649.
79. [79] Meanwell, N.A., Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. Chem. Res. Toxicol. 24 (2011), 1420–1456.
80. 2 agonists using parallel synthesis protocols: a lipophilic efficiency (LipE) analysis. Bioorg. Med. Chem. Lett. 19 (2009), 4406–4409.
81. [81] Ottaviani, G., Gosling, D.J., Patissier, C., Rodde, S., Zhou, L., Faller, B., What is modulating solubility in simulated intestinal fluids?. Eur. J. Pharm. Sci. 41 (2010), 452–457.
82. [82] Augustijns, P., Wuyts, B., Hens, B., Annaert, P., Butler, J., Brouwers, J., A review of drug solubility in human intestinal fluids: implications for the prediction of oral absorption. Eur. J. Pharm. Sci. 57 (2014), 322–332.
83. [83] Soderlind, E., Karlsson, E., Carlsson, A., Kong, R., Lenz, A., Lindborg, S., Sheng, J.J., Simulating fasted human intestinal fluids: understanding the roles of lecithin and bile acids. Mol. Pharm. 7 (2010), 1498–1507.
84. [84] Jantratid, E., Janssen, N., Reppas, C., Dressman, J.B., Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. Pharm. Res. 25 (2008), 1663–1676.
85. [85] Lennernas, H., Human intestinal permeability. J. Pharm. Sci. 87 (1998), 403–410.
86. [86] Clark, D.E., Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. J. Pharm. Sci. 88 (1999), 807–814.
87. [87] Paulis, L., Simko, F., Laudon, M., Cardiovascular effects of melatonin receptor agonists. Expert Opin. Investig. Drugs 21 (2012), 1661–1678.
88. [88] Sun, L.Q., Takaki, K., Chen, J., Iben, L., Knipe, J.O., Pajor, L., Mahle, C.D., Ryan, E., Xu, C., N-[2-[2-(4-phenylbutyl)benzofuran-4-yl]cyclopropylmethyl]acetamide: an orally bioavailable melatonin receptor agonist. Bioorg. Med. Chem. Lett. 14 (2004), 5157–5160.
89. [89] Porter, C.J., Pouton, C.W., Cuine, J.F., Charman, W.N., Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv. Drug Deliv. Rev. 60 (2008), 673–691.
90. [90] Perlman, M.E., Murdande, S.B., Gumkowski, M.J., Shah, T.S., Rodricks, C.M., Thornton-Manning, J., Freel, D., Erhart, L.C., Development of a self-emulsifying formulation that reduces the food effect for torcetrapib. Int. J. Pharm. 351 (2008), 15–22.
91. [91] Trevaskis, N.L., McEvoy, C.L., McIntosh, M.P., Edwards, G.A., Shanker, R.M., Charman, W.N., Porter, C.J., The role of the intestinal lymphatics in the absorption of two highly lipophilic cholesterol ester transfer protein inhibitors (CP524,515 and CP532,623). Pharm. Res. 27 (2010), 878–893.
92. [92] Kounnas, M.Z., Danks, A.M., Cheng, S., Tyree, C., Ackerman, E., Zhang, X., Ahn, K., Nguyen, P., Comer, D., Mao, L., Yu, C., Pleynet, D., Digregorio, P.J., Velicelebi, G., Stauderman, K.A., Comer, W.T., Mobley, W.C., Li, Y.M., Sisodia, S.S., Tanzi, R.E., Wagner, S.L., Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron 67 (2010), 769–780.
93. [93] Mitani, Y., Akashiba, H., Saita, K., Yarimizu, J., Uchino, H., Okabe, M., Asai, M., Yamasaki, S., Nozawa, T., Ishikawa, N., Shitaka, Y., Ni, K., Matsuoka, N., Pharmacological characterization of the novel gamma-secretase modulator AS2715348, a potential therapy for Alzheimer's disease, in rodents and nonhuman primates. Neuropharmacology 79 (2014), 412–419.
94. [94] Kuentz, M., Holm, R., Elder, D.P., Methodology of oral formulation selection in the pharmaceutical industry. Eur. J. Pharm. Sci., 2015.
95. [95] Wyttenbach, N., Alsenz, J., Grassmann, O., Miniaturized assay for solubility and residual solid screening (SORESOS) in early drug development. Pharm. Res. 24 (2007), 888–898.
96. [96] Wyttenbach, N., Janas, C., Siam, M., Lauer, M.E., Jacob, L., Scheubel, E., Page, S., Miniaturized screening of polymers for amorphous drug stabilization (SPADS): rapid assessment of solid dispersion systems. Eur. J. Pharm. Biopharm. 84 (2013), 583–598.
97. [97] O'Shea, J.P., Faisal, W., Ruane-O'Hora, T., Devine, K.J., Kostewicz, E.S., O'Driscoll, C.M., Griffin, B.T., Lipidic dispersion to reduce food dependent oral bioavailability of fenofibrate: in vitro, in vivo and in silico assessments. Eur. J. Pharm. Biopharm. 96 (2015), 207–216.
98. [98] Fei, Y., Kostewicz, E.S., Sheu, M.T., Dressman, J.B., Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach. Eur. J. Pharm. Biopharm. 85 (2013), 1274–1284.
99. [99] Zheng, W., Jain, A., Papoutsakis, D., Dannenfelser, R.M., Panicucci, R., Garad, S., Selection of oral bioavailability enhancing formulations during drug discovery. Drug Dev. Ind. Pharm. 38 (2012), 235–247.
100. [100] Yu, L., Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv. Drug Deliv. Rev. 48 (2001), 27–42.
101. [101] Miller, J.M., Beig, A., Carr, R.A., Spence, J.K., Dahan, A., A win–win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability. Mol. Pharm. 9 (2012), 2009–2016.
102. [102] Taylor, L.S., Zhang, G., Physical chemistry of supersaturated solutions and implications for oral absorption. Adv. Drug Deliv. Rev., 2016.
103. [103] Yamaguchi, T., Nishimura, M., Okamoto, R., Takeuchi, T., Yamamoto, K., Glass- formation of 4″-O-(4-methoxyphenyl)acetyltylosin and physicochemical stability of the amorphous solid. Int. J. Pharm. 85 (1992), 87–96.
104. [104] Zhang, F., Aaltonen, J., Tian, F., Saville, D.J., Rades, T., Influence of particle size and preparation methods on the physical and chemical stability of amorphous simvastatin. Eur. J. Pharm. Biopharm. 71 (2009), 64–70.
105. [105] Hancock, B.C., Shamblin, S.L., Zografi, G., Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures. Pharm. Res. 12 (1995), 799–806.
106. [106] Alzghoul, A., Alhalaweh, A., Mahlin, D., Bergstrom, C.A., Experimental and computational prediction of glass transition temperature of drugs. J. Chem. Inf. Model. 54 (2014), 3396–3403.
107. [107] Wang, R.Y., Pellerin, C., Lebel, O., Role of hydrogen bonding in the formation of glasses by small molecules: a triazine case study. J. Mater. Chem. 19 (2009), 2747–2753.
108. [108] Yamaoka, Y., Roberts, R.D., Stella, V.J., Low-melting phenytoin prodrugs as alternative oral delivery modes for phenytoin: a model for other high-melting sparingly water-soluble drugs. J. Pharm. Sci. 72 (1983), 400–405.
109. [109] Todeschini, R., Consonni, V., Molecular Descriptors for Chemoinformatics. 2009, WILEY-VCH, Weinheim.
110. [110] Baird, J.A., Van Eerdenbrugh, B., Taylor, L.S., A classification system to assess the crystallization tendency of organic molecules from undercooled melts. J. Pharm. Sci. 99 (2010), 3787–3806.
111. [111] Maria, T., Lopes Jesus, A., Eusébio, M., Glass-forming ability of butanediol isomers. Chem. Mater. Sci. 100 (2010), 385–390.
112. [112] Meunier, A., Lebel, O., A glass forming module for organic molecules: making tetraphenylporphyrin lose its crystallinity. Org. Lett. 12 (2010), 1896–1899.
113. [113] Alhalaweh, A., Alzghoul, A., Kaialy, W., Mahlin, D., Bergstrom, C.A., Computational predictions of glass-forming ability and crystallization tendency of drug molecules. Mol. Pharm. 11 (2014), 3123–3132.
114. [114] Mahlin, D., Bergstrom, C.A., Early drug development predictions of glass-forming ability and physical stability of drugs. Eur. J. Pharm. Sci. 49 (2013), 323–332.
115. [115] Wyttenbach, N., Kirchmeyer, W., Alsenz, J., Kuentz, M., Theoretical considerations of the prigogine–defay ratio with regard to the glass-forming ability of drugs from undercooled melts. Mol. Pharm. 13 (2016), 241–250.
116. [116] Nurzynska, K., Booth, J., Roberts, C.J., McCabe, J., Dryden, I., Fischer, P.M., Long-term amorphous drug stability predictions using easily calculated, predicted, and measured parameters. Mol. Pharm. 12 (2015), 3389–3398.
117. [117] Kaushal, A.M., Chakraborti, A.K., Bansal, A.K., FTIR studies on differential intermolecular association in crystalline and amorphous states of structurally related non-steroidal anti-inflammatory drugs. Mol. Pharm. 5 (2008), 937–945.
118. [118] Flory, P.J., Thermodynamics of high polymer solutions. J. Chem. Phys., 9, 1941, 660.
119. [119] Hansen, C.M., The three dimensional solubility parameter and solvent diffusion coefficient. Their importance in surface coating formulation. Den polytekniske Lrereanstalt, Danmarks tekniske Hojskole, 1967, Technical University of Denmark, Copenhagen, 106.
120. [120] Gupta, J., Nunes, C., Jonnalagadda, S., A molecular dynamics approach for predicting the glass transition temperature and plasticization effect in amorphous pharmaceuticals. Mol. Pharm. 10 (2013), 4136–4145.
121. [121] Xiang, T.X., Anderson, B.D., Molecular dynamics simulation of amorphous indomethacin–poly(vinylpyrrolidone) glasses: solubility and hydrogen bonding interactions. J. Pharm. Sci. 102 (2013), 876–891.
122. [122] Xiang, T.X., Anderson, B.D., Molecular dynamics simulation of amorphous hydroxypropyl-methylcellulose acetate succinate (HPMCAS): polymer model development, water distribution, and plasticization. Mol. Pharm. 11 (2014), 2400–2411.
123. [123] Xiang, T.X., Anderson, B.D., A molecular dynamics simulation of reactant mobility in an amorphous formulation of a peptide in poly(vinylpyrrolidone). J. Pharm. Sci. 93 (2004), 855–876.
124. [124] Xiang, T.X., Anderson, B.D., Water uptake, distribution, and mobility in amorphous poly(D,L-lactide) by molecular dynamics simulation. J. Pharm. Sci. 103 (2014), 2759–2771.
125. [125] Feeney, O.M., Crum, M.F., McEvoy, C.L., Trevaskis, N.L., Williams, H.D., Charman, W.N., Pouton, C.W., Bergstrom, C.A.S., Porter, C.J.P., 50 years of oral lipid-based formulations: provenance, progress, and future perspectives. Adv. Drug Deliv. Rev. 101 (2016), 167–194.
126. [126] Chen, X.Q., Gudmundsson, O.S., Hageman, M.J., Application of lipid-based formulations in drug discovery. J. Med. Chem. 55 (2012), 7945–7956.
127. [127] Yalkowsky, S.H., Flynn, G.L., Amidon, G.L., Solubility of nonelectrolytes in polar solvents. J. Pharm. Sci. 61 (1972), 983–984.
128. [128] Yalkowsky, S.H., Valvani, S.C., Amidon, G.L., Solubility of nonelectrolytes in polar solvents IV: nonpolar drugs in mixed solvents. J. Pharm. Sci. 65 (1976), 1488–1494.
129. [129] Patel, S.V., Patel, S., Prediction of the solubility in lipidic solvent mixture: investigation of the modeling approach and thermodynamic analysis of solubility. Eur. J. Pharm. Sci. 77 (2015), 161–169.
130. [130] Prajapati, H.N., Dalrymple, D.M., Serajuddin, A.T., A comparative evaluation of mono-, di- and triglyceride of medium chain fatty acids by lipid/surfactant/water phase diagram, solubility determination and dispersion testing for application in pharmaceutical dosage form development. Pharm. Res. 29 (2012), 285–305.
131. [131] Sacchetti, M., Nejati, E., Prediction of drug solubility in lipid mixtures from the individual ingredients. AAPS PharmSciTech 13 (2012), 1103–1109.
132. [132] Alskar, L.C., Porter, C.J., Bergstrom, C.A., Tools for early prediction of drug loading in lipid-based formulations. Mol. Pharm. 13 (2016), 251–261.
133. [133] King, D.T., Warren, D.B., Pouton, C.W., Chalmers, D.K., Using molecular dynamics to study liquid phase behavior: simulations of the ternary sodium laurate/sodium oleate/water system. Langmuir 27 (2011), 11381–11393.
134. [134] Warren, D.B., Chalmers, D.K., Pouton, C.W., Structure and dynamics of glyceride lipid formulations, with propylene glycol and water. Mol. Pharm. 6 (2009), 604–614.
135. [135] Warren, D.B., King, D., Benameur, H., Pouton, C.W., Chalmers, D.K., Glyceride lipid formulations: molecular dynamics modeling of phase behavior during dispersion and molecular interactions between drugs and excipients. Pharm. Res. 30 (2013), 3238–3253.
136. [136] Turner, D.C., Yin, F., Kindt, J.T., Zhang, H., Molecular dynamics simulations of glycocholate–oleic acid mixed micelle assembly. Langmuir 26 (2010), 4687–4692.
137. [137] Benson, S.P., Pleiss, J., Molecular dynamics simulations of self-emulsifying drug-delivery systems (SEDDS): influence of excipients on droplet nanostructure and drug localization. Langmuir 30 (2014), 8471–8480.
138. [138] Álvarez, S., Bourguet, W., Gronemeyer, H., de Lera, A.R., Retinoic acid receptor modulators: a perspective on recent advances and promises. Expert Opin. Ther. Pat. 21 (2011), 55–63.
139. [139] Berlin, M., Recent advances in the development of novel glucocorticoid receptor modulators. Expert Opin. Ther. Pat. 20 (2010), 855–873.
140. [140] Carpino, P.A., Goodwin, B., Diabetes area participation analysis: a review of companies and targets decribed in the 2008–2010 patent literature. Expert Opin. Ther. Pat. 20 (2010), 1627–1651.
141. [141] Cirino, G., Severino, B., Thrombin receptors and their antagonists: an update on the patent literature. Expert Opin. Ther. Pat. 20 (2010), 875–884.
142. [142] Crawley, M.L., Farnesoid X receptor modulators: a patent review. Expert Opin. Ther. Pat. 20 (2010), 1047–1057.
143. [143] Dai, Y., Platelet-derived growth factor receptor tyrosin kinase inhibitors: a review of the recent patent literature. Expert Opin. Ther. Pat. 20 (2010), 885–907.
144. [144] Escaich, S., Novel agents to inhibit microbial virulence and pathogenicity. Expert Opin. Ther. Pat. 20 (2010), 1401–1418.
145. B receptor positive modulators: a patent survey. Expert Opin. Ther. Pat. 20 (2010), 1007–1017.
146. [146] Giordanetto, F., Knerr, L., Wållberg, A., T-type calcium channels inhibitors. Expert Opin. Ther. Pat. 21 (2011), 85–101.
147. [147] Huang, S.-C., Korlipara, V.L., Neurokinin-1 receptor antagonists: a comprehensive patent survey. Expert Opin. Ther. Pat. 20 (2010), 1019–1045.
148. [148] Ivachtchenko, A.V., Ivanenkov, Y.A., Tkachenko, S.E., 5-Hydroxytryptamine subtype 6 receptor modulators: a patent survey. Expert Opin. Ther. Pat. 20 (2010), 1171–1196.
149. [149] Kirst, H.A., New macrolide, lincosaminide and streptogramin B antibiotics. Expert Opin. Ther. Pat. 20 (2010), 1343–1357.
150. 3 receptor antagonists/inverse agonists. Expert Opin. Ther. Pat. 20 (2010), 1147–1169.
151. [151] Lee, J., Jung, M.E., Lee, J., 5-HT2C receptor modulators: a patent survey. Expert Opin. Ther. Pat. 20 (2010), 1429–1455.
152. [152] Lee, J., Paek, S.-M., Han, S.-Y., FMS-like tyrosin kinase 3 inhibitors: a patent review. Expert Opin. Ther. Pat. 21 (2011), 483–503.
153. [153] Malherbe, P., Ballard, T.M., Ratni, H., Tachykinin neurokinin 3 receptor antagonists: a patent review (2005–2010). Expert Opin. Ther. Pat. 21 (2011), 637–655.
154. [154] Milkiewicz, K.L., Ott, G.R., Inhibitors of anaplastic lymphoma kinase: a patent review. Expert Opin. Ther. Pat. 20 (2010), 1653–1681.
155. 2 receptor antagonists. Expert Opin. Ther. Pat. 20 (2010), 1059–1077.
156. [156] Pettersson, M., Kauffman, G.W., Ende, C.W. am, Novel γ-secretase modulators: a review of patents from 2008 to 2010. Expert Opin. Ther. Pat. 21 (2011), 205–226.
157. [157] Poirer, D., 17β-Hydroxysteroid dehydrogenase inhibitors: a patent review. Expert Opin. Ther. Pat. 20 (2010), 1123–1145.
158. [158] Press, N.J., Fozard, J.R., Progress towards novel adenosine receptor therapeutics gleaned from the recent patent literature. Expert Opin. Ther. Pat. 20 (2010), 987–1005.
159. [159] Shen, H.C., Soluble epoxide hydrolase inhibitors: a patent review. Expert Opin. Ther. Pat. 20 (2010), 941–956.
160. [160] Singh, I.P., Chauthe, S.K., Small molecular HIV entry inhibitors: part II. Attachment and fusion inhibitors: 2004–2010. Expert Opin. Ther. Pat. 21 (2011), 399–416.
161. [161] Singh, I.P., Chauthe, S.K., Small molecule HIV entry inhibitors: part I. Chemokine receptor antagonists: 2004–2010. Expert Opin. Ther. Pat. 21 (2011), 227–269.
162. [162] Thakur, G.A., Tichkule, R., Bajaj, S., Makriyannis, A., Latest advances in cannabinoid receptor agonists. Expert Opin. Ther. Pat. 19 (2009), 1647–1673.
163. [163] Ulven, T., Kostenis, E., Novel CRTH2 antagonists: a review of patents from 2006 to 2009. Expert Opin. Ther. Pat. 20 (2010), 1505–1530.
164. [164] Wiles, J.A., Bradburt, B.J., Pucci, M.J., New quinolone antibiotics: a survey of the literature from 2005–2010. Expert Opin. Ther. Pat. 20 (2010), 1295–1319.
165. [165] Zhan, P., Liu, X., Novel HIV-1 non nucleoside reverse transcriptase inhibitors: a patent review (2005–2010). Expert Opin. Ther. Pat. 21 (2011), 717–796.